Alarming 50%+ of Americans could have diabetes or pre-diabetes at a cost of $3,350 billion by 2020

25 November 2010

More than 50% of Americans could have diabetes or pre-diabetes by 2020 at a cost of $3,350 billion over the next decade if current trends continue, according to new analysis by UnitedHealth Group’s Center for Health Reform & Modernization, but there are also practical solutions for slowing the trend.

New estimates show diabetes and pre-diabetes will account for an estimated 10% of total health care spending by the end of the decade at an annual cost of almost $500 billion - up from an estimated $194 billion this year.

The report, “The United States of Diabetes: Challenges and Opportunities in the Decade Ahead,” produced for this month's National Diabetes Awareness month, offers practical solutions that could improve health and life expectancy, while also saving up to $250 billion over the next 10 years, if programs to prevent and control diabetes are adopted broadly and scaled nationally. This figure includes $144 billion in potential savings to the federal government in Medicare, Medicaid and other public programs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical